Could Hyperactive Immune Cells Especially The Neutrophils Be the Reason For COVID-19 Fatalities?
COVID-19 Clinical Research
: A collaborative group of eleven international medical research organizations is investigating whether overactive immune cells that produce Neutrophil Extracellular Traps (NETs) cause the most severe cases. The consortium, called the NETwork, includes Cold Spring Harbor Laboratory, the Feinstein Institutes for Medical Research, and the Research Institute of the McGill University Health Centre (RI-MUHC).
Part of the body’s immune system, neutrophils detect bacteria and can expel their
DNA (see arrows) to attack the bacteria with a gauzy web of DNA laced with toxic
enzymes, called a NET. Credit: Egeblad lab/CSHL
A new research published in the Journal of Experimental Medicine
describes that patients with severe COVID-19 infection develop Acute Respiratory Distress Syndrome (ARDS), pulmonary inflammation, thick mucus secretions in the airways, extensive lung damage, and blood clots. https://rupress.org/jem/article/doi/10.1084/jem.20200652/151683/Targeting-potential-drivers-of-COVID19-Neutrophil
The critical late stage of the disease is difficult to manage. In the worst cases, patients require invasive mechanical ventilation, and still, a large number of patients die. The NETwork suggests that the severity of COVID-19 may result from overactive white blood cells known as the neutrophils. Part of the body’s immune system, neutrophils detect bacteria and can expel their DNA to attack the bacteria with a gauzy web of DNA laced with toxic enzymes, called a NET. These NETs can ensnare and digest the unwanted pathogen but in cases of ARDS, they damage the lungs and other organs.
Dr Betsy Barnes, Ph.D., lead and co-corresponding author of the paper and Professor at the Feinstein Institutes told Thailand Medical News, “Given the clear similarities between the clinical presentation of severe COVID-19 and other known diseases driven by NETs, such as ARDS, we propose that excess NETs may play a major role in the disease, As samples from patients become available, it will be important to determine whether the presence of NETs associates with disease severity and/or particular clinical characteristics of COVID-19.”
In the lungs, NETs drive the accumulation of mucus in cystic fibrosis patients’ airways.
NETs also drive acute respiratory distress syndrome (ARDS) after a variety of inducers
, including influenza. In the vascular system, NETs drive atherosclerosis and aortic
aneurysms, as well as thrombosis (particularly microthrombosis), with devastating
effects on organ function. BioRender was used to generate the illustration. Credit: CSHL
Biologist Dr Mikala Egeblad, Ph.D. from Cold Spring Harbor Laboratory cancer who coalesced the NETwork research group around COVID-19 and is senior and corresponding author of the paper said, “NETs were identified in 2004, but
many scientists have never heard of them. Most of the researchers in the NETwork have worked on NETs in other diseases, and when we started hearing about the symptoms of the COVID-19 patients, it sounded familiar.”
Dr Jonathan Spicer, M.D., Ph.D., a clinician scientist at the RI-MUHC and Assistant Professor of Surgery at McGill University is a thoracic surgeon who has witnessed the devastating effects of COVID-19 infection at the bedside.
He added, “We see in these patients severe lung damage known as ARDS, another serious problem caused by excess NETs and seen in cases of severe influenza. In addition, their airways are often clogged with thick mucus and unlike most severe lung infections, these patients tend to form small clots throughout their body at much higher rates than normal. NETs have also been found in the blood of patients with sepsis or cancer, where they can facilitate the formation of such blood clots.”
Medical researchers at the eleven NETwork institutions are now pursuing studies into whether NETs are a common feature in COVID-19 cases. If their findings show that excess NETs cause the severe symptoms of COVID-19, then a new avenue of treatments may be deployed to help COVID-19 patients. Current treatments used in other NET and neutrophil-driven diseases like cystic fibrosis, gout, and rheumatoid arthritis, might dampen the activity of NETs in COVID-19 patients, reducing the need for invasive mechanical ventilation.
For the latest on COVID-19 Clinical research
, keep logging on to Thailand Medical News
We desperately need your kind help! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. We are also trying to raise funds to help poor undocumented refugees who have no access to public healthcare during the COVID-19 crisis. Donations are accepted via paypal: https://www.thailandmedical.news/p/sponsorship